200 related articles for article (PubMed ID: 28592433)
1. Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia.
Zhang H; Chen Z; Miranda RN; Medeiros LJ; McCarty N
Blood; 2017 Aug; 130(6):763-776. PubMed ID: 28592433
[TBL] [Abstract][Full Text] [Related]
2. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
Chen Z; Pittman EF; Romaguera J; Fayad L; Wang M; Neelapu SS; McLaughlin P; Kwak L; McCarty N
PLoS One; 2013; 8(8):e69126. PubMed ID: 23936317
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1α pathway.
Argyriou P; Papageorgiou SG; Panteleon V; Psyrri A; Bakou V; Pappa V; Spathis A; Economopoulou P; Papageorgiou E; Economopoulos T; Rontogianni D
Ann Hematol; 2011 Mar; 90(3):315-22. PubMed ID: 20838824
[TBL] [Abstract][Full Text] [Related]
4. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
5. BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.
Zhang H; Zhang R; Zheng X; Sun M; Fan J; Fang C; Tian X; Zheng H
Cancer Sci; 2021 Mar; 112(3):1235-1250. PubMed ID: 33393145
[TBL] [Abstract][Full Text] [Related]
6. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
[TBL] [Abstract][Full Text] [Related]
7. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.
Feng M; Wang J; Sun M; Li G; Li B; Zhang H
Cancer Cell Int; 2021 May; 21(1):279. PubMed ID: 34039348
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
Xue M; Li X; Chen W
Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
[TBL] [Abstract][Full Text] [Related]
9. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
10. Tip110 Regulates the Cross Talk between p53 and Hypoxia-Inducible Factor 1α under Hypoxia and Promotes Survival of Cancer Cells.
Timani KA; Liu Y; Fan Y; Mohammad KS; He JJ
Mol Cell Biol; 2015 Jul; 35(13):2254-64. PubMed ID: 25939381
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
13. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.
Swaminathan S; Huang C; Geng H; Chen Z; Harvey R; Kang H; Ng C; Titz B; Hurtz C; Sadiyah MF; Nowak D; Thoennissen GB; Rand V; Graeber TG; Koeffler HP; Carroll WL; Willman CL; Hall AG; Igarashi K; Melnick A; Müschen M
Nat Med; 2013 Aug; 19(8):1014-22. PubMed ID: 23852341
[TBL] [Abstract][Full Text] [Related]
14. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.
Vegliante MC; Palomero J; Pérez-Galán P; Roué G; Castellano G; Navarro A; Clot G; Moros A; Suárez-Cisneros H; Beà S; Hernández L; Enjuanes A; Jares P; Villamor N; Colomer D; Martín-Subero JI; Campo E; Amador V
Blood; 2013 Mar; 121(12):2175-85. PubMed ID: 23321250
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.
Klanova M; Soukup T; Jaksa R; Molinsky J; Lateckova L; Maswabi BC; Prukova D; Brezinova J; Michalova K; Vockova P; Hernandez-Ilizaliturri F; Kulvait V; Zivny J; Vokurka M; Necas E; Trneny M; Klener P
Lab Invest; 2014 Jul; 94(7):806-17. PubMed ID: 24862967
[TBL] [Abstract][Full Text] [Related]
17. The Bach Family of Transcription Factors: A Comprehensive Review.
Zhou Y; Wu H; Zhao M; Chang C; Lu Q
Clin Rev Allergy Immunol; 2016 Jun; 50(3):345-56. PubMed ID: 27052415
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
[TBL] [Abstract][Full Text] [Related]
19. The Role of BACH2 in T Cells in Experimental Malaria Caused by
Edwards CL; de Oca MM; de Labastida Rivera F; Kumar R; Ng SS; Wang Y; Amante FH; Kometani K; Kurosaki T; Sidwell T; Kallies A; Engwerda CR
Front Immunol; 2018; 9():2578. PubMed ID: 30459773
[TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
